P-Glycoprotein Drives Glioblastoma Survival and Chemotherapy Resistance
The American Journal of Pathology · 2025-11 · 195 (11) · 2131-2142
DOI: 10.1016/j.ajpath.2024.12.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Pathology, 2025-11. Verfasst von Carlos Pilotto Heming und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro, Brazil; Post-Graduate Program in Anatomic Pathology, Faculdade de Medicina, Uni…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, FAPERJ.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Drug resistance is a major challenge in cancer therapy, and the expression of efflux pumps such as P-glycoprotein (P-gp, ABCB1) often correlates with poor prognosis in various tumors, including glioblastoma (GB). Considering that different roles for these proteins have been established in the biology of various tumors, this study aimed to investigate the functions of P-gp in GB-derived cells by evaluating its survival, migratory, and apoptosis-regulating capabilities, as well as its potential as a liquid biopsy biomarker. P-gp expression was diminished via siRNA to determine its exact role in GB biology. The P-gp mRNA levels were evaluated by using quantitative real-time RT-PCR. With respect to liquid biopsy, circulating cell-free RNA was extracted from plasma belonging to patients diagnosed with GB, and P-gp levels were compared with matching tumor tissues using digital PCR. P-gp silencing significantly decreased viability, increased apoptosis, and enhanced chemotherapy sensitivity in GB cells, although it did not affect migratory patterns. Finally, P-gp expression levels in circulating cell-free RNA from patients with GB matched tumor tissue, whereas healthy volunteers appeared to bear no circulating P-gp. Taken together, the results indicate that P-gp affects GB tumor biology beyond its known role in drug resistance and could integrate a broader molecular signature for future diagnosis via liquid biopsy.
Autor:innen und Institutionen
- Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro, Brazil; Post-Graduate Program in Anatomic Pathology, Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
- Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro, Brazil.
- Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Rio de Janeiro, Brazil; Post-Graduate Program in Anatomic Pathology, Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil. El…
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- FAPERJ
Zitieren
APA
Pilotto Heming, C., de Souza Barbosa, I., Lyra Miranda, R., Nogueira Ugarte, O., Santório de São José, V., Moura Neto, V., & Aran, V. (2025). P-Glycoprotein Drives Glioblastoma Survival and Chemotherapy Resistance. The American Journal of Pathology, 195(11), 2131-2142. https://doi.org/10.1016/j.ajpath.2024.12.004
Vancouver
Pilotto Heming C, de Souza Barbosa I, Lyra Miranda R, Nogueira Ugarte O, Santório de São José V, Moura Neto V, et al. P-Glycoprotein Drives Glioblastoma Survival and Chemotherapy Resistance. The American Journal of Pathology. 2025;195(11):2131-2142. doi:10.1016/j.ajpath.2024.12.004
BibTeX
@article{PilottoHeming2025,
author = {Pilotto Heming, Carlos and de Souza Barbosa, Isabel and Lyra Miranda, Renan and Nogueira Ugarte, Odile and Santório de São José, Vitória and Moura Neto, Vivaldo and Aran, Veronica},
title = {P-Glycoprotein Drives Glioblastoma Survival and Chemotherapy Resistance},
journal = {The American Journal of Pathology},
year = {2025},
volume = {195},
number = {11},
pages = {2131--2142},
doi = {10.1016/j.ajpath.2024.12.004}
}
EUVIMED